Overview
RCC Treatment Strategies in a Favorable-Risk Patient
A Whole New World of RCC: Are You Ready?
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
This activity is intended for medical oncologists, nephrologists, genitourinary cancer specialists, and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.
Given recent updates to treatment guidelines and the rapidly evolving treatment landscape in ccRCC, there is a need for ongoing clinical education to improve clinicians’ knowledge and confidence in treating patients appropriately. With challenges in clinical practice including appropriate therapy selection according to patient risk status and development of additional therapeutic options, clinicians need strategies and recommendations from expert clinicians to translate the rapidly evolving evidence, guidelines, and treatment landscape into practice. Learners post-activity will be better able to apply recent evidence and recommendations in practice within the context of multidisciplinary care and shared decision making.
Upon completion of this activity, participants will be able to:
• Discuss the major clinical trials that support the use of TKIs and immunotherapy for ccRCC
• Explain considerations for selecting a first-line treatment regimen for a patient with ccRCC, including biomarkers, adverse events, and medical comorbidities
• Apply clinical trial evidence and available recommendations to formulate tailored treatment regimens for advanced RCC
• Describe techniques and strategies for establishing shared decision-making in the selection of treatment for RCC
• Discuss the major clinical trials that support the use of TKIs and immunotherapy for ccRCC
• Explain considerations for selecting a first-line treatment regimen for a patient with ccRCC, including biomarkers, adverse events, and medical comorbidities
• Apply clinical trial evidence and available recommendations to formulate tailored treatment regimens for advanced RCC
• Describe techniques and strategies for establishing shared decision-making in the selection of treatment for RCC
This activity is supported by independent medical education grants from Exelixis, Inc., and Merck & Co., Inc..
Oguz Akin, MD
Professor of Radiology
Attending Radiologist
Memorial Sloan Kettering Cancer Center
New York, NY
Robert Motzer, MD
Attending Physician, Head, Kidney Cancer Section
Memorial Sloan Kettering Cancer Center
New York, NY
Elizabeth Plimack, MD, MS
Professor, Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA
Jay Raman, MD, FACS
Professor and Chief of Urology
Penn State College of Medicine
Penn State Health Milton S. Hershey Medical Center
Hershey, PA
Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Oguz Akin, MD
Ownership/Equity: Ezra AI
Robert Motzer, MD
Consultant (occasional): AstraZeneca, Aveo, Eli Lilly, EMD Serrono, Exelexis, Genentech/Roche, Merck
Trial support: Easai, Exelexis, Genentech/Roche, Merck
Jay Raman, MD, FACS
Trial support: MDx Health, Pacific Edge Biotechnologies, Urogen Pharma
Investment interest: United Medical Systems, Inc.
Elizabeth Plimack, MD, MS
Consultant (occasional): AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, Seattle Genetics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL, Penn State College of Medicine staff, and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6761-22-T.
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
